Stockwatch: Allos - Anatomy of an Acquisition
This article was originally published in Scrip
Spectrum Pharmaceuticals managed to mute the negative reaction to its two phase III failures for their bladder cancer therapy, apaziquone just before the weekend by announcing a $206 million acquisition of Allos Therapeutics (scripintelligence.com, 06 April 2012). Allos was previously the subject of a $260 million tug of war between AMAG and the Allos shareholders. That transaction was dissolved in four months, after counter-offers from, and lawsuits by, the Allos shareholders (scripintelligence.com, 21 November 2011). Paradoxically, a lower offer than that of AMAG seems to have already been accepted by about a quarter of Allos' shareholders on the basis of Spectrum's better stewardship of oncology assets.
You may also be interested in...
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.
Batsu is the Japanese term for games that have penalties, unlike those which are just for fun. Seasoned investors are well aware of the risks of drug and vaccine development but many investors new to the sector are just learning of the downsides.